Aeterna Zentaris (AEZS +2.8%) trades up after reporting that final Phase II data demonstrated...

|By:, SA News Editor

Aeterna Zentaris (AEZS +2.8%) trades up after reporting that final Phase II data demonstrated that its oral AKT inhibitor perifosine, when combined with sorafenib, was well tolerated by heavily pretreated lymphoma patients. Furthermore, promising clinical response activity was observed in patients with classical Hodgkin Lymphoma, suggesting that this subgroup could represent a target population for future studies.